Globus strengthens position as UK's leading force in hand protection
Progressing after 15 years in partnership with Showa Glove Company, UK leader in advanced hand protection solutions, Globus (Shetland) Ltd has announced an exciting addition to its market-leading portfolio.
From 1 March 2010 Globus has taken over all Showabest activities in the UK and Ireland. The addition of unique chemical protection products and the world's most advanced disposable glove offer gives Globus the only product portfolio that can claim the original iconic styles that created totally new markets for their distribution partners.
Grip style gloves, Palm Fit technology, Dyneema cut protective gloves and the world's first and patented disposable nitrile glove were all created by the Showabest organisation.
Innovative sales & marketing techniques have seen Globus rise to the forefront of the hand protection sector. Its customers now look set to enjoy the benefits of an invigorated range supported by UK stock and extensive sales support infrastructure.
You may also like
Manufacturing
UK pharmaceutical manufacturers struggling to meet F-Gas compliance amid ageing cooling infrastructure
Read moreA new Aggreko report reveals that nearly all UK pharmaceutical manufacturers are facing barriers to upgrading cooling systems ahead of the accelerating F-Gas phase-down timeline
Trending Articles
You may also like
Regulatory
UK REACH ATRm: CBA welcomes progress but warns of significant hurdles ahead
The Chemical Business Association has acknowledged long-awaited movement on the UK REACH Alternative Transitional Registration model following DEFRA's consultation response, but cautioned that cost burdens likely running into hundreds of millions of pounds
Regulatory
Lonza Nominates Stephen Fry as Independent Board Member
Basel, Switzerland, 31 March 2026 – The Lonza Board of Directors today announced the nomination of Stephen Fry as an Independent Member of the Board. Subject to his election at the Lonza Group Annual General Meeting (AGM) in May 2026, Stephen will also be appointed a member of the People and Governance Committee and the Audit and Compliance Committeex
Regulatory
FDA approves Lilly's oral GLP-1 pill Foundayo for obesity with no food or water restrictions
Eli Lilly has received FDA approval for Foundayo (orforglipron), a once-daily oral GLP-1 receptor agonist for adults with obesity or overweight that requires no fasting or water restrictions, with clinical trial participants on the highest dose losing an average of 27 pounds
Regulatory
FDA warns of drug-induced liver injury risk with Amgen's Tavneos after deaths
The US Food and Drug Administration has issued a safety warning linking Amgen's vasculitis drug Tavneos to 76 cases of drug-induced liver injury globally, including eight deaths and seven cases of vanishing bile duct syndrome, recommending comprehensive liver monitoring during the first five months of treatment
Regulatory
Pfizer's HYMPAVZI receives positive CHMP opinion for haemophilia A and B patients with inhibitors
The EMA's Committee for Medicinal Products for Human Use has recommended expanding the approved indication for Pfizer's HYMPAVZI to include adolescents and adults with haemophilia A or B who have developed inhibitors to factor replacement therapies
Regulatory
NICE approves KEYTRUDA as first perioperative immunotherapy for locally advanced head and neck cancer
MSD's KEYTRUDA (pembrolizumab) has received NICE approval as a neoadjuvant and adjuvant therapy for resectable LA HNSCC—the first immunotherapy recommended in this perioperative setting and the first treatment advance in more than two decades